Give people like Jennifer protection that lasts years

Jennifer&PartnerImage.png

Give Jennifer the protection she deserves with the only treatment providing nearly 3 years mPFS, more than 3 times longer vs crizotinib

  • 65 year-old grandmother 
  • Retired
  • Enjoys gardening
  • Lifelong non-smoker
  • Diagnosed with ALK+ advanced NSCLC 

Only ALECENSA 1L is proven to deliver
nearly 3 years free from progression1

protection-graph-1.jpg

Only ALECENSA 1L is proven to deliver nearly 3 years free from progression1

ALEX phase III: updated PFS analysis1

chart-alecensa-protection-1@2x.png

CI: confidence interval; ITT: intention-to-treat; mPFS: median progression-free survival; NE: not estimable.

1. Mok T et al. Ann Oncol. 2020;31(8):1056–64.

CI: confidence interval; ITT: intention-to-treat; mPFS: median progression-free survival; NE: not estimable.

1. Mok T et al. Ann Oncol. 2020;31(8):1056–64.

JenniferPhotoAlbumImage.png

People with ALK+ NSCLC need protection regardless of baseline CNS metastases. Only ALECENSA 1L provides >2 years mPFS for those with CNS metastases and >3 years  for those without, >3 times longer and >2.5 times longer than  crizotinib respectively

Efficacy that lasts for years regardless
of baseline CNS metastases1

protection-graph-2.jpg

Efficacy that lasts for years regardless of baseline CNS Metastases1

ALEX phase III: patients
WITH pre-existing CNS
metastases1

chart-alecensa-protection-2-a@3x.png

ALEX phase III: patients
WITHOUT pre-existing CNS
metastases1

chart-alecensa-protection-2-b@2x.png

CI: confidence interval; CNS: central nervous system; HR: hazard ratio; mPFS: median progression-free survival.

1. Mok T et al. Ann Oncol. 2020;31(8):1056–64.

CI: confidence interval; CNS: central nervous system; HR: hazard ratio; mPFS: median progression-free survival.

1. Mok T et al. Ann Oncol. 2020;31(8):1056–64.

JenniferinGardenImage.png

CNS progressive events can be particularly worrying for people with ALK+ NSCLC. ALECENSA reduces the rate of CNS events to below 10%, a remarkable 84% reduction vs crizotinib

ALECENSA 1L reduces the risk
of CNS progression*1

protection-graph-3.jpg

ALECENSA 1L reduces the risk of CNS progression*1

ALEX phase III:
cumulative incidence of
CNS progression (ITT
population)1

chart-alecensa-protection-3@2x.png

*At 1 year. †Cause specific hazard ratio; adjusted for competing risk of non-CNS progression and death. CI: confidence interval; CNS: central nervous system; HR: hazard ratio; ITT: intention-to-treat.

1. Peters S et al. N Engl J Med. 2017;377(9):829–38.

*At 1 year. †Cause specific hazard ratio; adjusted for competing risk of non-CNS progression and death. CI: confidence interval; CNS: central nervous system; HR: hazard ratio; ITT: intention-to-treat.

1. Peters S et al. N Engl J Med. 2017;377(9):829–38.

Continue to

Superior Survival